, Volume 66, Issue 13, pp 1752–1754 | Cite as

Extended-Release Intramuscular Naltrexone

A Viewpoint by Henry R. Kranzler
  • Henry R. Kranzler
Adis Drug Profile Guest Commentary



Supported by grant K24 AA13736 from the National Institute on Alcohol Abuse and Alcoholism. Dr. Kranzler has received support for research and has served as a consultant or speaker for the following companies: Alkermes, Inc., Bristol-Myers Squibb Co., DrugAbuse Sciences, Forest Laboratories and Ortho-McNeil Pharmaceuticals.


  1. 1.
    Garbutt JC, Kranzler HR, O’Malley SS, et al. Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial. JAMA 2005 Apr; 293(13): 1617–25PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2006

Authors and Affiliations

  • Henry R. Kranzler
    • 1
  1. 1.University of Connecticut School of MedicineFarmingtonUSA

Personalised recommendations